Keros Therapeutics (KROS) News Today $14.65 +0.08 (+0.55%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$14.49 -0.16 (-1.09%) As of 05/2/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Boxer Capital Management LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)Boxer Capital Management LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 250,000 shares of the company's stMay 4 at 6:25 AM | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Tower Research Capital LLC TRCTower Research Capital LLC TRC grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,149.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,984 shares of the company's stock after acqMay 4 at 4:01 AM | marketbeat.comImplied Volatility Surging for Keros Therapeutics Stock OptionsMay 2 at 12:16 PM | theglobeandmail.comTCG Crossover Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)TCG Crossover Management LLC trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 550,000 shares of the cMay 1 at 8:03 AM | marketbeat.comDarwin Global Management Ltd. Has $26.71 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Darwin Global Management Ltd. raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,687,135 shares of the company's stock after buying an adMay 1 at 8:03 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Acquires 42,734 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Mutual Fund Advisers Trust grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,347 shares of the company's stock after purchMay 1 at 7:19 AM | marketbeat.comLynx1 Capital Management LP Buys New Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Lynx1 Capital Management LP purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 544,001 shares of the company's stock, valued at approxiApril 29, 2025 | marketbeat.comNebula Research & Development LLC Increases Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Nebula Research & Development LLC raised its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 433.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 71,710 shares of the company's stoApril 29, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Boosted by Blue Owl Capital Holdings LPBlue Owl Capital Holdings LP boosted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 97.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 242,633 shares of the company's stock after purApril 26, 2025 | marketbeat.comRussell Investments Group Ltd. Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Russell Investments Group Ltd. reduced its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 67.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,321 shares of the companApril 26, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives $40.33 Average PT from BrokeragesApril 25, 2025 | americanbankingnews.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating and eight have issuedApril 24, 2025 | marketbeat.comGeode Capital Management LLC Raises Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Geode Capital Management LLC lifted its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 765,436 shares of the company's stock after purchasingApril 23, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 182,314 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)JPMorgan Chase & Co. grew its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 585.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213,431 shares of the company's stock afApril 23, 2025 | marketbeat.comAltium Capital Management LLC Has $2.77 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Altium Capital Management LLC lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 153.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 175,000 shares of the company's stock after acquiring an additional 106,000 shares duApril 20, 2025 | marketbeat.comWalleye Capital LLC Makes New Investment in Keros Therapeutics, Inc. (NASDAQ:KROS)Walleye Capital LLC purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 197,666 shares of the company's stock, valued at approximately $3,129April 20, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Alliancebernstein L.P. trimmed its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 13.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 137,424 shares of the company's stock after selling 20,781 sApril 19, 2025 | marketbeat.comInsider Buying: Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Purchases 934,258 Shares of StockKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.April 16, 2025 | marketbeat.comVanguard Group Inc. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Vanguard Group Inc. raised its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,957,109 shares of the company's stock after purApril 16, 2025 | marketbeat.comAdar1 Capital Management, Llc Acquires 934,258 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) StockApril 15, 2025 | insidertrades.comFederated Hermes Inc. Purchases New Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Federated Hermes Inc. purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 124,620 shares of the company's stock, valued at approximately $1,973,000. FederaApril 15, 2025 | marketbeat.comNorges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Norges Bank acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 64,900 shares of the company's stock, valued at approximately $1,02April 14, 2025 | marketbeat.comKeros Therapeutics Target of Unusually Large Options Trading (NASDAQ:KROS)Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors purchased 4,215 put options on the company. This is an increase of 287% compared to the average daily volume of 1,090 put options.April 13, 2025 | marketbeat.comKeros Therapeutics: Strategic Alternatives Could Bring About Value CreationApril 11, 2025 | seekingalpha.comTruist Financial Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock PriceTruist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research report on Wednesday.April 11, 2025 | marketbeat.comKeros reviewing strategic alternatives, adopts shareholder rights planApril 10, 2025 | markets.businessinsider.comKeros Therapeutics, Inc.: Keros Therapeutics Announces Review of Strategic AlternativesApril 10, 2025 | finanznachrichten.deKeros Therapeutics stock jumps on strategic review, potential saleApril 10, 2025 | investing.comKeros Therapeutics price target lowered to $25 from $43 at TruistApril 10, 2025 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Keros Therapeutics (KROS)April 10, 2025 | markets.businessinsider.comKeros climbs after strategic review; adopts poison pillApril 10, 2025 | msn.comKeros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s OverjoyedApril 10, 2025 | msn.comKeros Therapeutics adopts 'poison pill' planApril 10, 2025 | reuters.comKeros Therapeutics adopts 'poison pill' planApril 10, 2025 | reuters.comKeros Therapeutics Announces Review of Strategic AlternativesApril 10, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by ADAR1 Capital Management LLCADAR1 Capital Management LLC trimmed its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 94.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,246 shareApril 9, 2025 | marketbeat.comBryce Point Capital LLC Invests $445,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)Bryce Point Capital LLC bought a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 28,127 shares of the company's stock, valued at approximately $April 7, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases 31,251 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)American Century Companies Inc. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,920 shares of the company'sApril 6, 2025 | marketbeat.comClearbridge Investments LLC Invests $3.01 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Clearbridge Investments LLC acquired a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 190,064 shares of the company's stockApril 5, 2025 | marketbeat.comWedbush Reiterates Neutral Rating for Keros Therapeutics (NASDAQ:KROS)Wedbush reiterated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Tuesday.April 2, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Keros Therapeutics (NASDAQ:KROS)HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Keros Therapeutics in a research note on Tuesday.April 2, 2025 | marketbeat.com2KROS : Forecasting The Future: 7 Analyst Projections For Keros TherapeuticsApril 1, 2025 | benzinga.comKeros Therapeutics reports results from Phase 1 clinical trial of KER-065March 31, 2025 | markets.businessinsider.comKeros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy VolunteersMarch 31, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from BrokeragesKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fourteen analysts that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the cMarch 29, 2025 | marketbeat.comEmerald Advisers LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Advisers LLC raised its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 57.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,633 shares of the company's stock afterMarch 25, 2025 | marketbeat.com29,146 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 29,146 shares of tMarch 23, 2025 | marketbeat.comKeros Therapeutics: Losing Its Lead Drug Is Bad MedicineMarch 13, 2025 | seekingalpha.comKeros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from AnalystsKeros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to theMarch 3, 2025 | marketbeat.comFY2026 EPS Estimate for Keros Therapeutics Lifted by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2026 earnings per share (EPS) estimates for Keros Therapeutics in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now anticipates that the comMarch 3, 2025 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼1.550.73▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼85▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ImmunityBio News Twist Bioscience News Biohaven News Recursion Pharmaceuticals News Amneal Pharmaceuticals News Metsera News Ascentage Pharma Group International News Apellis Pharmaceuticals News Denali Therapeutics News Kymera Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts